Press Release Archive - R&D News

R&D News

12.06.2006
Lexapro(R) Demonstrated Significance on Prospectively Defined Efficacy Parameter and Was Better Tolerated Than Cymbalta(R) in Treatment of Depression
10.27.2006
Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2
10.25.2006
Patient Recruitment for Desmoteplase Phase IIB/III Stroke Study DIAS-2 Placed on Hold
04.10.2006
Forest and Almirall Announce a Development and Marketing Collaboration Agreement on New Therapy for COPD
02.15.2006
Forest Laboratories Revises Research and Development Spending Projection to Account for Upfront Payments for Two Recent In-Licensing Transactions
01.05.2006
Forest Laboratories, Inc. and Cypress Bioscience, Inc. to Commence Third Milnacipran Phase III Trial
04.15.2005
Campral(R) is Safe and Well-Tolerated in Long-Term Treatment of Alcohol Dependence According to Results Presented at American Society of Addiction Medicine Conference
02.09.2005
Forest Laboratories Starts Confirmatory Study of Desmoteplase A Novel Investigational Treatment For Acute, Ischemic Stroke
11.22.2004
Gedeon Richter and Forest Laboratories Announce Collaboration Agreement on Atypical Antipsychotic for Schizophrenia, Bipolar Mania and Other Psychiatric Disorders
01.20.2004
JAMA Reports Alzheimer's Patients Treated With Combination of Namenda(TM) (Memantine HCl) and Donepezil Experienced Significant Benefits Compared to Donepezil Alone